Frankfurt
17.03.25 | 08:52
3,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.12.25 | OPTHEA LIMITED: Change of Director's Interest Notice - KC & LG | - | ASX | ||
| OPTHEA LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 19.12.25 | OPTHEA LIMITED: Notification regarding unquoted securities - OPT | 1 | ASX | ||
| 17.12.25 | Health Check: No longer sheepish, Opthea flags fresh start | 2 | Stockhead | ||
| 17.12.25 | OPTHEA LIMITED: Investor Update Presentation | 1 | ASX | ||
| 11.12.25 | OPTHEA LIMITED: Notice of Market Update | 16 | ASX | ||
| 07.12.25 | OPTHEA LIMITED: Change in substantial holding | - | ASX | ||
| 20.11.25 | OPTHEA LIMITED: Voluntary delisting from Nasdaq takes effect | 1 | ASX | ||
| 20.11.25 | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 12.11.25 | Opthea Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 11.11.25 | OPTHEA LIMITED: Results of AGM | 1 | ASX | ||
| 10.11.25 | Opthea Ltd - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | - | SEC Filings | ||
| 30.10.25 | OPTHEA LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 30.10.25 | Opthea Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 29.10.25 | OPTHEA LIMITED: Opthea announces intention to delist from Nasdaq | - | ASX | ||
| 27.10.25 | Opthea Appoints Hamish George As CFO | - | RTTNews | ||
| 26.10.25 | OPTHEA LIMITED: Appointment of Company Secretary and CFO | 1 | ASX | ||
| 15.10.25 | OPTHEA LIMITED: Long Term Suspended Entities | 1 | ASX | ||
| 09.10.25 | OPTHEA LIMITED: Notice of Annual General Meeting/Proxy Form | - | ASX | ||
| 06.10.25 | Opthea Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.10.25 | OPTHEA LIMITED: Opthea Receives A$10.8 million R&D Tax Incentive | 2 | ASX |
1 2 Weiter >>
40 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 15,730 | -0,19 % | Palatin Technologies, Inc.: Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update | Significant progress on multiple fronts - obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,700 | 0,00 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| HALOZYME THERAPEUTICS | 59,28 | -1,20 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer | RYBREVANT FASPRO is approved across all indications of RYBREVANT® (amivantamab-vmjw)
SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:... ► Artikel lesen | |
| ABCELLERA BIOLOGICS | 2,933 | +0,62 % | AbCellera Biologics Inc. - 8-K, Current Report | ||
| GLOW LIFETECH | 0,030 | 0,00 % | Glow Lifetech Corp.: Glow Lifetech Reports Record Q3 2025 Financial Results; 193% YoY Revenue Growth and Achieves First Positive Cash Flow from Operations | Toronto, Ontario--(Newsfile Corp. - November 25, 2025) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to report its financial results for the third... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 255,70 | -1,88 % | Biodesix, Inc.: Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital PCR High Complexity Assays | LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which... ► Artikel lesen | |
| AVID BIOSERVICES | 12,100 | 0,00 % | Avid Bioservices appoints Dave Stewart as Chief Technology and Transformation Officer | The newly created role marks a major step in CEO Kenneth Bilenberg's vision to scale Avid for its next chapter of growth.
TUSTIN, Calif., Nov. 10, 2025 /PRNewswire/... ► Artikel lesen | |
| BIOLINERX | 2,110 | -5,38 % | BioLineRx Ltd.: BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Establishes joint venture with Hemispherian AS to advance GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,500 | +3,55 % | Minerva Neurosciences, Inc: Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company's Board of Directors | BURLINGTON, Mass., Nov. 19, 2025(Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced the appointment... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 1,940 | -9,35 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer | Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic
MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk... ► Artikel lesen | |
| APPLIED THERAPEUTICS | 0,086 | -2,72 % | Cycle Pharmaceuticals to Acquire Applied Therapeutics | NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT; "Applied"), a clinical-stage biopharmaceutical company dedicated to creating transformative treatments for rare... ► Artikel lesen | |
| OVID THERAPEUTICS | 1,380 | -8,00 % | Ovid Therapeutics is a buy, this analyst says | ||
| GEOVAX LABS | 0,207 | +21,05 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| COCRYSTAL | 0,820 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus | Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis... ► Artikel lesen |
OPTHEA LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 3,000 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OPTHEA LIMITED ADR finden Sie auf Wallstreet Online.